Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × Bortezomib × Clear all

Phase

Status

Completed 45 Terminated 11 Active not recruiting 3 Withdrawn 2 Not yet recruiting 2 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 32 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Recurrence 4 Immunoglobulin Light-chain Amyloidosis 4 Neoplasms, Plasma Cell 3 Hematologic Neoplasms 3 Renal Insufficiency 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia, Myeloid, Acute 2 Breast Neoplasms 2 beta-Thalassemia 1 Waldenstrom Macroglobulinemia 1 Thalassemia 1 Plasmablastic Lymphoma 1 Peripheral Nervous System Diseases 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, Biphenotypic, Acute 1 Burkitt Lymphoma 1 Anemia, Sickle Cell 1 Amyloidosis 1 Acute-Phase Reaction 1

Interventions

Cyclophosphamide 27 fludarabine 18 Rituximab 17 obinutuzumab 11 venetoclax 10 Lenalidomide 9 Bendamustine Hydrochloride 9 Prednisone 7 zanubrutinib 6 Doxorubicin 6 Blood Specimen Collection 6 pembrolizumab 5 ibrutinib 5 Exercise 5 Biopsy 5 fludarabine phosphate 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 loncastuximab tesirine 3 glofitamab 3 gamma-Globulins 3 axicabtagene ciloleucel 3 acalabrutinib 3 Therapeutics 3 Temozolomide 3 Surveys and Questionnaires 3 Palliative Care 3 Methotrexate 3 Mesna 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡